Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash from Investing Activities (2016 - 2025)

Rocket Pharmaceuticals' Cash from Investing Activities history spans 10 years, with the latest figure at $36.4 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 196.18% year-over-year to $36.4 million; the TTM value through Dec 2025 reached $103.8 million, down 21.21%, while the annual FY2025 figure was $103.8 million, 21.21% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was $36.4 million at Rocket Pharmaceuticals, down from $93.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $93.6 million in Q3 2025 and bottomed at -$140.8 million in Q4 2023.
  • The 5-year median for Cash from Investing Activities is $27.3 million (2022), against an average of $4.3 million.
  • The largest annual shift saw Cash from Investing Activities surged 1008.04% in 2021 before it crashed 743.89% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at $16.9 million in 2021, then tumbled by 743.89% to -$108.6 million in 2022, then dropped by 29.67% to -$140.8 million in 2023, then skyrocketed by 73.1% to -$37.9 million in 2024, then skyrocketed by 196.18% to $36.4 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Cash from Investing Activities are $36.4 million (Q4 2025), $93.6 million (Q3 2025), and $31.8 million (Q2 2025).